Latest Innovation News

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

EROAD Limited’s CEO Mark Heine has announced his resignation effective June 2026, concluding an 11-year tenure marked by significant company growth across multiple regions.

Oakridge International Limited has reported a striking turnaround in its half-year results, posting a profit after tax of $172,239 against a prior loss, driven by strong sales and product innovation in healthcare technology.

HighCom Limited has announced a $7 million capital raise alongside a $1 million Share Purchase Plan to support working capital and product innovation, aiming for a strong revenue rebound and profitability in the second half of FY26.

HighCom Limited has announced a successful A$7 million placement alongside a new Share Purchase Plan, aiming to accelerate sales and manufacturing upgrades in key markets.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

National Storage REIT delivered robust half-year results with earnings and occupancy gains, while agreeing to a premium acquisition offer from Brookfield-GIC consortium.

Brazilian Rare Earths has confirmed a breakthrough low-temperature acid-cure process achieving up to 97% rare earth extraction at just 150°C, promising lower costs and enhanced scalability for its Brazilian operations.

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.